FASL antibody

Catalog No. ABIN2749018

This anti-FASL antibody is a Mouse Monoclonal antibody detecting FASL in WB, FACS, IP, ICC and Func. Suitable for Human. This Primary Antibody has been cited in 5+ publications.

Quick Overview for FASL antibody (ABIN2749018)

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FASL antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP), Immunocytochemistry (ICC), Functional Studies (Func)

Clone: NOK-1

Product Details anti-FASL Antibody

Purpose: Anti-Hu CD178 Purified Low Endotoxin

Specificity: The mouse monoclonal antibody NOK-1 recognizes an extracellular epitope of CD178 / Fas-L, an approximately 40 kDa transmembrane glycoprotein expressed on neutrophils, monocytes, and activated T and NK cells.

Cross-Reactivity (Details): Human

Purification: Purified by protein-A affinity chromatography.

Purity: > 95 % (by SDS-PAGE)

Endotoxin Level: Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.

Immunogen: L5178Y mouse T lymphoma cells expressing recombinant human CD178

Isotype: IgG1

Application Details

Application Notes: Functional application: Blocking.
Flow cytometry: Recommended dilution: 1-4 μg/mL

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4

Storage: 4 °C

Storage Comment: Store at 2-8°C. Do not freeze.

References for anti-FASL antibody (ABIN2749018)

Ji, Chen, Braciale, Cloyd: "Apoptosis induced in HIV-1-exposed, resting CD4+ T cells subsequent to signaling through homing receptors is Fas/Fas ligand-mediated." in: Journal of leukocyte biology, Vol. 81, Issue 1, pp. 297-305, (2006) (PubMed).

Jodo, Pidiyar, Xiao, Furusaki, Sharma, Koike, Ju: "Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand-mediated cytotoxicity." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 174, Issue 8, pp. 4470-4, (2005) (PubMed).

Chopin, Barei-Moniri, Maillé, Le Frère-Belda, Muscatelli-Groux, Merendino, Lecerf, Stoppacciaro, Velotti: "Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression." in: The American journal of pathology, Vol. 162, Issue 4, pp. 1139-49, (2003) (PubMed).

Ghadimi, Sanzenbacher, Thiede, Wenzel, Jing, Plomann, Borkhardt, Kabelitz, Janssen: "Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178)." in: FEBS letters, Vol. 519, Issue 1-3, pp. 50-8, (2002) (PubMed).

Kayagaki, Kawasaki, Ebata, Ohmoto, Ikeda, Inoue, Yoshino, Okumura, Yagita: "Metalloproteinase-mediated release of human Fas ligand." in: The Journal of experimental medicine, Vol. 182, Issue 6, pp. 1777-83, (1996) (PubMed).

Target Details for FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Alternative Name: CD178

Background: Fas ligand,CD178 / Fas-L (Fas ligand, CD95L), a member of TNF family transmembrane glycoproteins, is responsible for induction of apoptosis in cells containing its receptor CD95 / Fas. The CD178-mediated apoptosis pathway has been implicated in peripheral tolerance, tissue pathology, and maintenance of the immune privileged sites. Defects in this interaction may be related to some cases of systemic lupus erythematosus (SLE). CD178 was also described as a co-stimulatory receptor for T-cell activation in mice in vivo.,APTL, FASL, FAS-ligand, CD95L, TNFSF6, TNLG1A

Gene ID: 356

UniProt: P48023

Pathways: Apoptosis, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity